Landos Biopharma Inc (LABP)
22.46
+0.16
(+0.72%)
USD |
NASDAQ |
May 17, 16:00
22.46
0.00 (0.00%)
After-Hours: 20:00
Landos Biopharma Cash from Operations (TTM): -20.80M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -20.80M |
December 31, 2023 | -20.48M |
September 30, 2023 | -19.21M |
June 30, 2023 | -24.55M |
March 31, 2023 | -37.44M |
December 31, 2022 | -45.77M |
September 30, 2022 | -54.13M |
Date | Value |
---|---|
June 30, 2022 | -58.40M |
March 31, 2022 | -31.00M |
December 31, 2021 | -27.06M |
September 30, 2021 | -23.40M |
June 30, 2021 | -16.93M |
March 31, 2021 | -32.15M |
December 31, 2020 | -22.96M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-58.40M
Minimum
Jun 2022
-16.93M
Maximum
Jun 2021
-31.02M
Average
-25.81M
Median
Cash from Operations (TTM) Benchmarks
AbbVie Inc | 22.69B |
Fusion Pharmaceuticals Inc | -83.67M |
Masimo Corp | 139.50M |
Kinnate Biopharma Inc (DELISTED) | -100.04M |
Invivyd Inc | -182.20M |